UK

Despite that sale, Theravance retained rights to receive 85% of Trelegy royalties on sales from 2029 onward outside the U.S., and from 2031 in the U.S.

Under the agreement, Alchemab will manage the initial clinical development through early Phase I trials, after which Lilly will take over later-stage development, regulatory approvals, and global commercialization.

This ambitious project, estimated to cost around £1 billion (approximately US$1.25 billion), aims to transform a 12-acre site in Sutton into a global centre for cancer research, treatment, and enterprise.

This approval follows a streamlined international recognition procedure, which allowed the UK to acknowledge the vaccine’s recent approval by the European Commission.

Blenrep is now approved in the UK for use in combination with bortezomib plus dexamethasone (BVd) in patients who have received at least one prior therapy, and in combination with pomalidomide plus dexamethasone (BPd) for those who have previously received lenalidomide.

Tessellate Bio will receive an upfront licensing fee, research funding, and milestone payments, with total potential value exceeding US$572 million through success-based payments tied to development and commercial milestones.

ATMPs consist of innovative treatments developed from cells, genes, or tissues and are often utilized for rare diseases and certain types of cancer.

Schizophrenia is a chronic and debilitating mental disorder marked by symptoms such as delusions, hallucinations, and disordered thinking.